undamentalytics Newsletter
Sign in

Sutro Biopharma, Inc. cash flow statement

In fiscal 2025, Sutro Biopharma, Inc.'s operations generated −$177m of cash; it spent $0 on capital projects, leaving free cash flow of −$177m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−13−3713−65−68−824−112−192−177−145
Depreciation and amortisation65554567776
Stock-based pay113101223262525147
Capital spending43200000000
Free cash flow−18−4011−65−68−824−112−192−177−145
Free cash flow after stock pay−19−428−75−80−105−23−137−216−191−152
Share buybacks—————0—————
Shares issued———−0251—00250—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SPRO vs STROEDIT vs STROLXRX vs STRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sutro Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sutro Biopharma, Inc.